Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f(®) in healthy women after follicle-stimulating hormone downregulation

BACKGROUND: XM17 is a recombinant human follicle-stimulating hormone (rhFSH) intended mainly for use in controlled ovarian hyperstimulation and the treatment of anovulation. The purpose of the current study was to establish bioequivalence, safety and tolerability of single 300-IU subcutaneous (sc) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammerich, Andreas, Mueller, Arnd, Bias, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665917/
https://www.ncbi.nlm.nih.gov/pubmed/26621118
http://dx.doi.org/10.1186/s12958-015-0124-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665917/
https://www.ncbi.nlm.nih.gov/pubmed/26621118
http://dx.doi.org/10.1186/s12958-015-0124-y

Ejemplares similares